Cite
HARVARD Citation
Dunn, T. et al. (2016). A phase 1, open‐label, dose‐escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British journal of haematology. pp. 253-259. [Online].